Journal
ONCOGENE
Volume 40, Issue 19, Pages 3422-3433Publisher
SPRINGERNATURE
DOI: 10.1038/s41388-021-01656-1
Keywords
-
Funding
- National Natural Science Foundation of China (NSFC) [81772501, 81972576]
- RGC-CRF Hong Kong [C7065-18G]
- CUHK
- Shenzhen Virtual University Park Support Scheme
- [MOST-2016YFC1303200]
Ask authors/readers for more resources
This study identified LIMK1 as a key promoter of gastric cancer peritoneal metastasis and suggested dabrafenib as a potential therapeutic target. The findings showed that targeting LIMK1 with dabrafenib could inhibit migration and invasion of gastric cancer cells in vitro and prevent metastasis in vivo, by suppressing phosphorylation of cofilin.
Peritoneal metastasis is a common form of metastasis among advanced gastric cancer patients. In this study, we reported the identification of LIM domain kinase 1 (LIMK1) as a promoter of gastric cancer peritoneal metastasis, and its potential to be a therapeutic target of dabrafenib (DAB). Using transcriptomic sequencing of paired gastric cancer peritoneal metastasis, primary tumors, and normal gastric tissues, we first unveiled that LIMK1 is selectively up-regulated in metastatic tumors. Increased LIMK1 in gastric cancer peritoneal metastasis was validated by immunohistochemistry analysis of an independent patient cohort. In vitro functional studies demonstrated that LIMK1 knockout or knockdown significantly inhibited cell migration and invasion of gastric cancer cells. LIMK1 knockout also abrogated peritoneal and liver metastases of gastric cancer cells in nude mice in vivo. Dabrafenib, a small molecule targeting LIMK1, was found to decrease cell migration and invasion of gastric cancer cells in vitro and abolish peritoneal and liver metastasis formation in vivo. Mechanistically, either LIMK1 knockout or Dabrafenib inhibited LIMK1 expression and phosphorylation of its downstream target cofilin. Taken together, our results demonstrated that LIMK1 functions as a metastasis promoter in gastric cancer by inhibiting LIMK1-p-cofilin and that Dabrafenib has the potential to serve as a novel treatment for gastric cancer peritoneal metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available